Published :
Tables : 52
Figures : 47
Category : Healthcare
No. of Pages : 233
Report Code : HC-1296
Active Pharmaceutical Ingredient (API) Market is estimated to register a CAGR of over 5.8% during the forecast period 2022 to 2028. An abundance of capital is needed for the production of API, as the procedures require very systematic and precise protocols. As a result, there is no focus on physical manpower and setting up of costly manufacturing units. By adopting tactful and strategic outsourcing, the companies can emphasize more on their competencies, thereby, culminating in heightened productivity. Active pharmaceutical ingredients (APIs) which have good quality, are crucial for the production of safe and effective medicines. However, it should be noted that not all pharmaceutical companies have adopted their own individual API manufacturing units. According to the market analysis, the rise of ailments such as cardiovascular and periodontal diseases, back pain, cancer and dental caries are factors which are expected to propel the active pharmaceutical ingredient market growth. The need for affordable medication and the rise in the volume of ANDA filings is projected to augment the market. The acceptance of biologics and biosimilars and the rise in ailments such as cancer and chronic diseases, are factors which have been predicted to drive the market. However, aspects such as strict regulatory bodies and intense competition among other players, coupled with issues relating to price control regulations are all likely to pose potential threats to the market growth. Some major global players in the APIs market include Pfizer, Inc., Novartis International AG, Sanofi, Boehringer Ingelheim, Bristol-Myers Squibb, Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, GlaxoSmithKline plc, Merck & Co., Inc., AbbVie Inc., F. Hoffmann-La Roche Ltd., AstraZeneca, Cipla, Inc., Mylan N.V., Dr. Reddy’s Laboratories Ltd, Sun Pharmaceutical Industries Ltd., API Pharma Tech, BDR Pharmaceuticals Internationals Pvt. Ltd., Sreepathi Pharmaceuticals Limited, Shilpa Medicare Limited, Albemarle Corporation, Viatris Inc., Aurobindo Pharma, Dr. Reddy’s Laboratories Ltd., Biocon Active Pharmaceutical Ingredient (API) Market Segmentation: By Drug Type • Prescription Drugs • Over-the-counter Drugs By Manufacturer • Captive (In-House) Manufacturer • Merchant (Contract) Manufacturer By Therapeutic Application • Communicable Diseases • Oncology • Diabetes • Cardiovascular Disease • Pain management • Respiratory Diseases • Other Therapeutic Applications By End-User • Pharmaceutical & Biotechnology Industry • Contract Research Organizations • Contract Manufacturing Organizations • Other End-User By Synthesis • Synthetic o Type • Innovative Synthetic API • Generic Synthetic API • Biotech o Type • Innovative Synthetic API • Generic Synthetic API o Product • Monoclonal Antibodies • Hormones • Cytokines • Recombinant Proteins • Therapeutic Enzymes • Vaccines • Blood Factors o Expression System • Mammalian Expression Systems • Microbial Expression Systems • Yeast Expression Systems • Insect Expression Systems • Other Expression Systems By Region North America Europe Asia- Pacific Latin America Middle East and Africa Competitive Landscape: • Tier 1 players- established companies in the market with a major market share • Tier 2 players • Emerging players which are growing rapidly • New Entrants FutureWise Key Takeaways: Growth prospects SWOT analysis Key trends Key data-points affecting market growth Objectives of the Study: To provide with an exhaustive analysis on the active pharmaceuticals market by drug type, by manufacturer, by therapeutic application, by end-user, by synthesis and by region To cater comprehensive information on factors impacting market growth (drivers, restraints, industry-specific restraints and opportunities) To forecast and evaluate micro-markets and the overall market To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa To record, evaluate and analyse competitive landscape mapping- technological advancements, product launches, expansions and mergers Flexible Delivery Model: We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement The customization Mobility Care offered are free of charge with purchase of any license of the report You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
An abundance of capital is needed for the production of API, as the procedures require very systematic and precise protocols. As a result, there is no focus on physical manpower and setting up of costly manufacturing units. By adopting tactful and strategic outsourcing, the companies can emphasize more on their competencies, thereby, culminating in heightened productivity.
Active pharmaceutical ingredients (APIs) which have good quality, are crucial for the production of safe and effective medicines. However, it should be noted that not all pharmaceutical companies have adopted their own individual API manufacturing units. According to the market analysis, the rise of ailments such as cardiovascular and periodontal diseases, back pain, cancer and dental caries are factors which are expected to propel the active pharmaceutical ingredient market growth. The need for affordable medication and the rise in the volume of ANDA filings is projected to augment the market.
The acceptance of biologics and biosimilars and the rise in ailments such as cancer and chronic diseases, are factors which have been predicted to drive the market. However, aspects such as strict regulatory bodies and intense competition among other players, coupled with issues relating to price control regulations are all likely to pose potential threats to the market growth.
Some major global players in the APIs market include Pfizer, Inc., Novartis International AG, Sanofi, Boehringer Ingelheim, Bristol-Myers Squibb, Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, GlaxoSmithKline plc, Merck & Co., Inc., AbbVie Inc., F. Hoffmann-La Roche Ltd., AstraZeneca, Cipla, Inc., Mylan N.V., Dr. Reddy’s Laboratories Ltd, Sun Pharmaceutical Industries Ltd., API Pharma Tech, BDR Pharmaceuticals Internationals Pvt. Ltd., Sreepathi Pharmaceuticals Limited, Shilpa Medicare Limited, Albemarle Corporation, Viatris Inc., Aurobindo Pharma, Dr. Reddy’s Laboratories Ltd., Biocon
Active Pharmaceutical Ingredient (API) Market Segmentation:
By Drug Type • Prescription Drugs • Over-the-counter Drugs
By Manufacturer • Captive (In-House) Manufacturer • Merchant (Contract) Manufacturer
By Therapeutic Application • Communicable Diseases • Oncology • Diabetes • Cardiovascular Disease • Pain management • Respiratory Diseases • Other Therapeutic Applications
By End-User • Pharmaceutical & Biotechnology Industry • Contract Research Organizations • Contract Manufacturing Organizations • Other End-User
By Synthesis • Synthetic o Type • Innovative Synthetic API • Generic Synthetic API • Biotech o Type • Innovative Synthetic API • Generic Synthetic API o Product • Monoclonal Antibodies • Hormones • Cytokines • Recombinant Proteins • Therapeutic Enzymes • Vaccines • Blood Factors o Expression System • Mammalian Expression Systems • Microbial Expression Systems • Yeast Expression Systems • Insect Expression Systems • Other Expression Systems
By Region
Competitive Landscape:
• Tier 1 players- established companies in the market with a major market share • Tier 2 players • Emerging players which are growing rapidly • New Entrants
FutureWise Key Takeaways:
Objectives of the Study:
Flexible Delivery Model:
1. Market Introduction 1.1. Objectives of the Study 1.2. Market Definition 1.3. Market Scope 1.3.1. Years Considered for the Study 1.3.2. Market Covered 1.4. Currency 1.5. Limitations 1.6. Stakeholders 2. Research Methodology 2.1. Research Data 2.1.1. Secondary Data 2.1.1.1. Key Data from Secondary Sources 2.1.2. Primary Data 2.1.2.1. Key Data from Primary Sources 2.2. Market Size Estimation 2.3. Market Breakdown and Data Triangulation 2.4. Assumptions for the Study 3. Executive Summary 3.1. Market Outlook 3.2. Segment Outlook 3.3. Competitive Insights 4. Active Pharmaceutical Ingredient (API) Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances 5. Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Active Pharmaceutical Ingredient (API) Market Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework 6. Active Pharmaceutical Ingredient (API) Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies 7. Active Pharmaceutical Ingredient (API) Market, By Drug Type Historical Analysis and Forecast 2022-2028 (USD Million) 7.1. Prescription Drugs 7.2. Over-the-counter Drugs 8. Active Pharmaceutical Ingredient (API) Market, By Manufacturer Historical Analysis and Forecast 2022-2028 (USD Million) 8.1. Captive (In-House) Manufacturer 8.2. Merchant (Contract) Manufacturer 9. Active Pharmaceutical Ingredient (API) Market, By Therapeutic Application Historical Analysis and Forecast 2022-2028 (USD Million) 9.1. Communicable Diseases 9.2. Oncology 9.3. Diabetes 9.4. Cardiovascular Disease 9.5. Pain management 9.6. Respiratory Diseases 9.7. Other Therapeutic Applications 10. Active Pharmaceutical Ingredient (API) Market, By End-User Historical Analysis and Forecast 2022-2028 (USD Million) 10.1. Pharmaceutical & Biotechnology Industry 10.2. Contract Research Organizations 10.3. Contract Manufacturing Organizations 10.4. Other End-User 11. Active Pharmaceutical Ingredient (API) Market, By Synthesis Historical Analysis and Forecast 2022-2028 (USD Million) 11.1. Synthetic 11.1.1. Type 11.1.1.1. Innovative Synthetic API 11.1.1.2. Generic Synthetic API 11.2. Biotech 11.2.1. Type 11.2.1.1. Innovative Synthetic API 11.2.1.2. Generic Synthetic API 11.2.2. Product 11.2.2.1. Monoclonal Antibodies 11.2.2.2. Hormones 11.2.2.3. Cytokines 11.2.2.4. Recombinant Proteins 11.2.2.5. Therapeutic Enzymes 11.2.2.6. Vaccines 11.2.2.7. Blood Factors 11.2.3. Expression System 11.2.3.1. Mammalian Expression Systems 11.2.3.2. Microbial Expression Systems 11.2.3.3. Yeast Expression Systems 11.2.3.4. Insect Expression Systems 11.2.3.5. Other Expression Systems 12. North America Active Pharmaceutical Ingredient (API) Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 12.2.1. U.S.A 12.2.2. Canada 12.2.3. Mexico 12.3. Market Size (USD Million) Forecast for North America 2022-2028 13. Latin America Active Pharmaceutical Ingredient (API) Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 13.2.1. Brazil 13.2.2. Venezuela 13.2.3. Argentina 13.2.4. Rest of Latin America 13.3. Market Size (USD Million) Forecast for Latin America 2022-2028 14. Europe Active Pharmaceutical Ingredient (API) Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 14.2.1. Germany 14.2.2. U.K 14.2.3. France 14.2.4. Italy 14.2.5. Spain 14.2.6. Russia 14.2.7. Poland 14.2.8. Rest of Europe 14.3. Market Size (USD Million) Forecast for Europe 2022-2028 15. Asia Pacific Active Pharmaceutical Ingredient (API) Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 15.1. Introduction 15.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 15.2.1. Japan 15.2.2. China 15.2.3. India 15.2.4. Australia and New Zealand 15.2.5. ASEAN 15.2.6. Rest of Asia Pacific 15.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028 16. Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 16.1. Introduction 16.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 16.2.1. GCC 16.2.2. Israel 16.2.3. South Africa 16.2.4. Rest of MEA 16.3. Market Size (USD Million) Forecast for MEA 2022-2028 17. Market Share Analysis and Competitive Landscape 17.1. Global Landscape - Key Players, Revenue and Presence 17.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3) 17.3. Global Emerging Companies 17.4. North America - Market Share Analysis and Key Regional Players 17.5. Europe - Market Share Analysis and Key Regional Players 17.6. Asia Pacific - Market Share Analysis and Key Regional Players 17.7. Global Key Player - Growth Matrix 18. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts) 18.1. Pfizer, Inc. 18.1.1. Company Overview 18.1.2. Product Portfolio 18.1.3. SWOT Analysis 18.1.4. Financial Overview 18.1.5. Strategic Overview 18.2. Novartis International AG 18.2.1. Company Overview 18.2.2. Product Portfolio 18.2.3. SWOT Analysis 18.2.4. Financial Overview 18.2.5. Strategic Overview 18.3. Sanofi 18.3.1. Company Overview 18.3.2. Product Portfolio 18.3.3. SWOT Analysis 18.3.4. Financial Overview 18.3.5. Strategic Overview 18.4. Boehringer Ingelheim 18.4.1. Company Overview 18.4.2. Product Portfolio 18.4.3. SWOT Analysis 18.4.4. Financial Overview 18.4.5. Strategic Overview 18.5. Bristol-Myers Squibb 18.5.1. Company Overview 18.5.2. Product Portfolio 18.5.3. SWOT Analysis 18.5.4. Financial Overview 18.5.5. Strategic Overview 18.6. Teva Pharmaceutical Industries Ltd. 18.6.1. Company Overview 18.6.2. Product Portfolio 18.6.3. SWOT Analysis 18.6.4. Financial Overview 18.6.5. Strategic Overview 18.7. Eli Lilly and Company 18.7.1. Company Overview 18.7.2. Product Portfolio 18.7.3. SWOT Analysis 18.7.4. Financial Overview 18.7.5. Strategic Overview 18.8. GlaxoSmithKline plc 18.8.1. Company Overview 18.8.2. Product Portfolio 18.8.3. SWOT Analysis 18.8.4. Financial Overview 18.8.5. Strategic Overview 18.9. Merck & Co., Inc. 18.9.1. Company Overview 18.9.2. Product Portfolio 18.9.3. SWOT Analysis 18.9.4. Financial Overview 18.9.5. Strategic Overview 18.10. AbbVie Inc. 18.10.1. Company Overview 18.10.2. Product Portfolio 18.10.3. SWOT Analysis 18.10.4. Financial Overview 18.10.5. Strategic Overview 18.11. F. Hoffmann-La Roche Ltd. 18.11.1. Company Overview 18.11.2. Product Portfolio 18.11.3. SWOT Analysis 18.11.4. Financial Overview 18.11.5. Strategic Overview 18.12. AstraZeneca 18.12.1. Company Overview 18.12.2. Product Portfolio 18.12.3. SWOT Analysis 18.12.4. Financial Overview 18.12.5. Strategic Overview 18.13. Cipla, Inc. 18.13.1. Company Overview 18.13.2. Product Portfolio 18.13.3. SWOT Analysis 18.13.4. Financial Overview 18.13.5. Strategic Overview 18.14. Mylan N.V. 18.14.1. Company Overview 18.14.2. Product Portfolio 18.14.3. SWOT Analysis 18.14.4. Financial Overview 18.14.5. Strategic Overview 18.15. Dr. Reddy’s Laboratories Ltd 18.15.1. Company Overview 18.15.2. Product Portfolio 18.15.3. SWOT Analysis 18.15.4. Financial Overview 18.15.5. Strategic Overview 18.16. Sun Pharmaceutical Industries Ltd. 18.16.1. Company Overview 18.16.2. Product Portfolio 18.16.3. SWOT Analysis 18.16.4. Financial Overview 18.16.5. Strategic Overview 18.17. API Pharma Tech 18.17.1. Company Overview 18.17.2. Product Portfolio 18.17.3. SWOT Analysis 18.17.4. Financial Overview 18.17.5. Strategic Overview 18.18. BDR Pharmaceuticals Internationals Pvt. Ltd. 18.18.1. Company Overview 18.18.2. Product Portfolio 18.18.3. SWOT Analysis 18.18.4. Financial Overview 18.18.5. Strategic Overview 18.19. Sreepathi Pharmaceuticals Limited 18.19.1. Company Overview 18.19.2. Product Portfolio 18.19.3. SWOT Analysis 18.19.4. Financial Overview 18.19.5. Strategic Overview 18.20. Shilpa Medicare Limited 18.20.1. Company Overview 18.20.2. Product Portfolio 18.20.3. SWOT Analysis 18.20.4. Financial Overview 18.20.5. Strategic Overview 18.21. Albemarle Corporation 18.21.1. Company Overview 18.21.2. Product Portfolio 18.21.3. SWOT Analysis 18.21.4. Financial Overview 18.21.5. Strategic Overview 18.22. Viatris Inc. 18.22.1. Company Overview 18.22.2. Product Portfolio 18.22.3. SWOT Analysis 18.22.4. Financial Overview 18.22.5. Strategic Overview 18.23. Aurobindo Pharma 18.23.1. Company Overview 18.23.2. Product Portfolio 18.23.3. SWOT Analysis 18.23.4. Financial Overview 18.23.5. Strategic Overview 18.24. Dr. Reddy’s Laboratories Ltd. 18.24.1. Company Overview 18.24.2. Product Portfolio 18.24.3. SWOT Analysis 18.24.4. Financial Overview 18.24.5. Strategic Overview 18.25. Biocon 18.25.1. Company Overview 18.25.2. Product Portfolio 18.25.3. SWOT Analysis 18.25.4. Financial Overview 18.25.5. Strategic Overview 19. Pre and Post COVID-19 Impact 19.1. Positive influence on the healthcare industry 19.2. The financial disruption of the manufacturing sector 19.3. Impact of COVID-19 on emerging companies 19.4. Significant mandates in the healthcare regulations initiated by administrations 19.5. The overall economic slowdown of the developing and developed nations 20. FutureWise SME Key Takeaway Points for Client
1. Market Introduction 1.1. Objectives of the Study 1.2. Market Definition 1.3. Market Scope 1.3.1. Years Considered for the Study 1.3.2. Market Covered 1.4. Currency 1.5. Limitations 1.6. Stakeholders
2. Research Methodology 2.1. Research Data 2.1.1. Secondary Data 2.1.1.1. Key Data from Secondary Sources 2.1.2. Primary Data 2.1.2.1. Key Data from Primary Sources 2.2. Market Size Estimation 2.3. Market Breakdown and Data Triangulation 2.4. Assumptions for the Study
3. Executive Summary 3.1. Market Outlook 3.2. Segment Outlook 3.3. Competitive Insights
4. Active Pharmaceutical Ingredient (API) Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances
5. Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Active Pharmaceutical Ingredient (API) Market Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework
6. Active Pharmaceutical Ingredient (API) Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies
7. Active Pharmaceutical Ingredient (API) Market, By Drug Type Historical Analysis and Forecast 2022-2028 (USD Million) 7.1. Prescription Drugs 7.2. Over-the-counter Drugs
8. Active Pharmaceutical Ingredient (API) Market, By Manufacturer Historical Analysis and Forecast 2022-2028 (USD Million) 8.1. Captive (In-House) Manufacturer 8.2. Merchant (Contract) Manufacturer
9. Active Pharmaceutical Ingredient (API) Market, By Therapeutic Application Historical Analysis and Forecast 2022-2028 (USD Million) 9.1. Communicable Diseases 9.2. Oncology 9.3. Diabetes 9.4. Cardiovascular Disease 9.5. Pain management 9.6. Respiratory Diseases 9.7. Other Therapeutic Applications
10. Active Pharmaceutical Ingredient (API) Market, By End-User Historical Analysis and Forecast 2022-2028 (USD Million) 10.1. Pharmaceutical & Biotechnology Industry 10.2. Contract Research Organizations 10.3. Contract Manufacturing Organizations 10.4. Other End-User
11. Active Pharmaceutical Ingredient (API) Market, By Synthesis Historical Analysis and Forecast 2022-2028 (USD Million) 11.1. Synthetic 11.1.1. Type 11.1.1.1. Innovative Synthetic API 11.1.1.2. Generic Synthetic API 11.2. Biotech 11.2.1. Type 11.2.1.1. Innovative Synthetic API 11.2.1.2. Generic Synthetic API 11.2.2. Product 11.2.2.1. Monoclonal Antibodies 11.2.2.2. Hormones 11.2.2.3. Cytokines 11.2.2.4. Recombinant Proteins 11.2.2.5. Therapeutic Enzymes 11.2.2.6. Vaccines 11.2.2.7. Blood Factors 11.2.3. Expression System 11.2.3.1. Mammalian Expression Systems 11.2.3.2. Microbial Expression Systems 11.2.3.3. Yeast Expression Systems 11.2.3.4. Insect Expression Systems 11.2.3.5. Other Expression Systems
12. North America Active Pharmaceutical Ingredient (API) Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 12.2.1. U.S.A 12.2.2. Canada 12.2.3. Mexico 12.3. Market Size (USD Million) Forecast for North America 2022-2028
13. Latin America Active Pharmaceutical Ingredient (API) Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 13.2.1. Brazil 13.2.2. Venezuela 13.2.3. Argentina 13.2.4. Rest of Latin America 13.3. Market Size (USD Million) Forecast for Latin America 2022-2028
14. Europe Active Pharmaceutical Ingredient (API) Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 14.2.1. Germany 14.2.2. U.K 14.2.3. France 14.2.4. Italy 14.2.5. Spain 14.2.6. Russia 14.2.7. Poland 14.2.8. Rest of Europe 14.3. Market Size (USD Million) Forecast for Europe 2022-2028
15. Asia Pacific Active Pharmaceutical Ingredient (API) Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 15.1. Introduction 15.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 15.2.1. Japan 15.2.2. China 15.2.3. India 15.2.4. Australia and New Zealand 15.2.5. ASEAN 15.2.6. Rest of Asia Pacific 15.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028
16. Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 16.1. Introduction 16.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 16.2.1. GCC 16.2.2. Israel 16.2.3. South Africa 16.2.4. Rest of MEA 16.3. Market Size (USD Million) Forecast for MEA 2022-2028
17. Market Share Analysis and Competitive Landscape 17.1. Global Landscape - Key Players, Revenue and Presence 17.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3) 17.3. Global Emerging Companies 17.4. North America - Market Share Analysis and Key Regional Players 17.5. Europe - Market Share Analysis and Key Regional Players 17.6. Asia Pacific - Market Share Analysis and Key Regional Players 17.7. Global Key Player - Growth Matrix
18. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts) 18.1. Pfizer, Inc. 18.1.1. Company Overview 18.1.2. Product Portfolio 18.1.3. SWOT Analysis 18.1.4. Financial Overview 18.1.5. Strategic Overview 18.2. Novartis International AG 18.2.1. Company Overview 18.2.2. Product Portfolio 18.2.3. SWOT Analysis 18.2.4. Financial Overview 18.2.5. Strategic Overview 18.3. Sanofi 18.3.1. Company Overview 18.3.2. Product Portfolio 18.3.3. SWOT Analysis 18.3.4. Financial Overview 18.3.5. Strategic Overview 18.4. Boehringer Ingelheim 18.4.1. Company Overview 18.4.2. Product Portfolio 18.4.3. SWOT Analysis 18.4.4. Financial Overview 18.4.5. Strategic Overview 18.5. Bristol-Myers Squibb 18.5.1. Company Overview 18.5.2. Product Portfolio 18.5.3. SWOT Analysis 18.5.4. Financial Overview 18.5.5. Strategic Overview 18.6. Teva Pharmaceutical Industries Ltd. 18.6.1. Company Overview 18.6.2. Product Portfolio 18.6.3. SWOT Analysis 18.6.4. Financial Overview 18.6.5. Strategic Overview 18.7. Eli Lilly and Company 18.7.1. Company Overview 18.7.2. Product Portfolio 18.7.3. SWOT Analysis 18.7.4. Financial Overview 18.7.5. Strategic Overview 18.8. GlaxoSmithKline plc 18.8.1. Company Overview 18.8.2. Product Portfolio 18.8.3. SWOT Analysis 18.8.4. Financial Overview 18.8.5. Strategic Overview 18.9. Merck & Co., Inc. 18.9.1. Company Overview 18.9.2. Product Portfolio 18.9.3. SWOT Analysis 18.9.4. Financial Overview 18.9.5. Strategic Overview 18.10. AbbVie Inc. 18.10.1. Company Overview 18.10.2. Product Portfolio 18.10.3. SWOT Analysis 18.10.4. Financial Overview 18.10.5. Strategic Overview 18.11. F. Hoffmann-La Roche Ltd. 18.11.1. Company Overview 18.11.2. Product Portfolio 18.11.3. SWOT Analysis 18.11.4. Financial Overview 18.11.5. Strategic Overview 18.12. AstraZeneca 18.12.1. Company Overview 18.12.2. Product Portfolio 18.12.3. SWOT Analysis 18.12.4. Financial Overview 18.12.5. Strategic Overview 18.13. Cipla, Inc. 18.13.1. Company Overview 18.13.2. Product Portfolio 18.13.3. SWOT Analysis 18.13.4. Financial Overview 18.13.5. Strategic Overview 18.14. Mylan N.V. 18.14.1. Company Overview 18.14.2. Product Portfolio 18.14.3. SWOT Analysis 18.14.4. Financial Overview 18.14.5. Strategic Overview 18.15. Dr. Reddy’s Laboratories Ltd 18.15.1. Company Overview 18.15.2. Product Portfolio 18.15.3. SWOT Analysis 18.15.4. Financial Overview 18.15.5. Strategic Overview 18.16. Sun Pharmaceutical Industries Ltd. 18.16.1. Company Overview 18.16.2. Product Portfolio 18.16.3. SWOT Analysis 18.16.4. Financial Overview 18.16.5. Strategic Overview 18.17. API Pharma Tech 18.17.1. Company Overview 18.17.2. Product Portfolio 18.17.3. SWOT Analysis 18.17.4. Financial Overview 18.17.5. Strategic Overview 18.18. BDR Pharmaceuticals Internationals Pvt. Ltd. 18.18.1. Company Overview 18.18.2. Product Portfolio 18.18.3. SWOT Analysis 18.18.4. Financial Overview 18.18.5. Strategic Overview 18.19. Sreepathi Pharmaceuticals Limited 18.19.1. Company Overview 18.19.2. Product Portfolio 18.19.3. SWOT Analysis 18.19.4. Financial Overview 18.19.5. Strategic Overview 18.20. Shilpa Medicare Limited 18.20.1. Company Overview 18.20.2. Product Portfolio 18.20.3. SWOT Analysis 18.20.4. Financial Overview 18.20.5. Strategic Overview 18.21. Albemarle Corporation 18.21.1. Company Overview 18.21.2. Product Portfolio 18.21.3. SWOT Analysis 18.21.4. Financial Overview 18.21.5. Strategic Overview 18.22. Viatris Inc. 18.22.1. Company Overview 18.22.2. Product Portfolio 18.22.3. SWOT Analysis 18.22.4. Financial Overview 18.22.5. Strategic Overview 18.23. Aurobindo Pharma 18.23.1. Company Overview 18.23.2. Product Portfolio 18.23.3. SWOT Analysis 18.23.4. Financial Overview 18.23.5. Strategic Overview 18.24. Dr. Reddy’s Laboratories Ltd. 18.24.1. Company Overview 18.24.2. Product Portfolio 18.24.3. SWOT Analysis 18.24.4. Financial Overview 18.24.5. Strategic Overview 18.25. Biocon 18.25.1. Company Overview 18.25.2. Product Portfolio 18.25.3. SWOT Analysis 18.25.4. Financial Overview 18.25.5. Strategic Overview
19. Pre and Post COVID-19 Impact 19.1. Positive influence on the healthcare industry 19.2. The financial disruption of the manufacturing sector 19.3. Impact of COVID-19 on emerging companies 19.4. Significant mandates in the healthcare regulations initiated by administrations 19.5. The overall economic slowdown of the developing and developed nations
20. FutureWise SME Key Takeaway Points for Client
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics